Skip to main content

CombiMatrix Signs Biodefense CRADA with USAMRIID

NEW YORK, Nov. 18 (GenomeWeb News) - Acacia Research subsidiary CombiMatrix said today that it has signed a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to develop microarray technology for environmental and medical detection of biothreat agents.

Financial details of the CRADA were not disclosed.

Under the agreement, USAMRIID and CombiMatrix will share consultative services, equipment, reagents, and testing support to demonstrate the effectiveness of CombiMatrix's Electrochemical Detection System for identifying biothreat agents. USAMRIID will provide appropriate reagents to CombiMatrix during the project for live agent testing in USAMRIID's secure facilities.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.